MARKET

MRK

MRK

Merck & Co
NYSE
125.26
-0.59
-0.47%
After Hours: 125.26 0 0.00% 19:55 07/26 EDT
OPEN
127.24
PREV CLOSE
125.85
HIGH
128.73
LOW
125.05
VOLUME
6.47M
TURNOVER
0
52 WEEK HIGH
134.63
52 WEEK LOW
97.23
MARKET CAP
317.26B
P/E (TTM)
140.41
1D
5D
1M
3M
1Y
5Y
1D
Catalyst Watch: Tech blitz with Apple, Amazon, Microsoft, and Meta on tap for earnings
Seeking Alpha's Catalyst Watch looks at next week's key events. Options trading volume is elevated on Container Store and Allbirds ahead of their earnings reports. McDonald's, Microsoft, and Boeing among companies due to report on July 29 and 30. Mark Zuckerberg will speak at the SIGGRAPH Conference in Denver.
Seeking Alpha · 6h ago
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
NASDAQ · 11h ago
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
NASDAQ · 12h ago
Pfizer, Merck bladder cancer therapy endorsed for approval in EU
Merck's Keytruda in combination with Pfizer's Padcev for bladder cancer therapy endorsed for approval in EU. The European Medicines Agency has endorsed the therapy for a type of bladder cancer. The decision was based on interim data from a Phase 3 trial.
Seeking Alpha · 12h ago
Dividend Roundup: Wells Fargo, General Motors, Merck, Delta Air Lines, and more
Dividend Stocks News Dividend Roundup: Wells Fargo, General Motors, Merck, Delta Air Lines, and more this week. This week's dividend activity included increased payouts from Wells Fargo and Bank of America. Companies such as General Motors and Merck also declared dividends. Looking towards next week, industry players like Delta Air lines and Morgan Stanley will see the ex-dividend dates for their upcoming payments.
Seeking Alpha · 13h ago
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of KEYTRUDA for the first-line treatment of adult patients with urothelial carcinoma. The recommendation is based on results from the Phase 3 KEYNOTE-A39 trial. The European Commission will now review the recommendation for marketing authorization in the EU.
Barchart · 19h ago
Viking Stock Jumps After Company Speeds Development Its Weight-Loss Pill
Barron‘s · 1d ago
Noteworthy ETF Outflows: IWB, JPM, JNJ, MRK
NASDAQ · 1d ago
More
About MRK
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products include therapeutic and preventive agents, sold by prescription, for the treatment of human disorders. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3, an inhibitory canonical Notch ligand. Its lead candidate, Restoret, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway.

Webull offers Merck & Co Inc stock information, including NYSE: MRK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRK stock methods without spending real money on the virtual paper trading platform.